Initiating GLP-1 Therapy in Combination with FreeStyle Libre Provides Greater Benefit Compared with GLP-1 Therapy Alone
Diabetes Technology & Therapeutics · 2024-10 · 26 (10) · 754-762
DOI: 10.1089/dia.2024.0015 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Diabetes Technology & Therapeutics, online erschienen am 04.10.2024. Verfasst von Eugene E Wright und 5 weiteren Autor:innen. Beteiligte Einrichtung: South Piedmont AHEC, Charlotte, North Carolina, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemic Agents, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Aim: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) therapy provides glycemic benefits to individuals with type 2 diabetes (T2D). However, the effects of GLP-1 RA therapy in combination with FreeStyle Libre systems (FSL) are unknown. This study aimed to compare changes in hemoglobin A1c (HbA1c) between people acquiring GLP-1 with FSL (GLP-1+FSL) versus GLP-1 without FSL (GLP-1).
Methods
This real-world study used Optum’s de-identified Market Clarity Data, a linked electronic health records (EHR)-claims database, and included adults with T2D and HbA1c ≥8% who acquired their first GLP-1 RA medication between 2018 and 2022. GLP-1+FSL subjects acquired their first FSL within ±30 days of their first GLP-1 acquisition. Cohorts were matched 1:5 on baseline insulin therapy, age, sex, baseline HbA1c, and GLP-1 type. Paired changes in HbA1c were compared between unmatched and matched groups at 6 months.
Results
The study included 24,724 adults in the unmatched cohort (GLP-1+FSL, n = 478; GLP-1, n = 24,246). The matched cohort included 478 GLP-1+FSL users and 2,390 GLP-1 users: mean age 53.5 ± 11.8 and 53.5 ± 11.3 years, HbA1c 10.25 ± 1.68% and 10.22 ± 1.69%, respectively. HbA1c reduction was greater in the GLP-1+FSL group compared with the GLP-1 group in the unmatched cohort (−2.43% vs. −1.73%, difference 0.70%, P < 0.001, respectively) and in the matched cohort (−2.43% vs. −2.06%, difference 0.37%, P < 0.001). GLP-1+FSL vs. GLP-1 treatment was associated with greater HbA1c reduction in the intensive insulin (−2.32% vs. −1.50%), nonintensive insulin (−2.50% vs. −1.74%), and noninsulin group (−2.46% vs. −1.78%), as well as in patients using semaglutide (−2.73% vs. −1.92%) and dulaglutide (−2.45% vs. −1.71%) GLP-1 RA, all P < 0.001.
Conclusions
Adults with suboptimally controlled T2D, initiating GLP-1 RA with FreeStyle Libre, had greater improvement in HbA1c compared with those treated with GLP-1 RA only. These results suggest an additional glycemic benefit of FSL when used with a GLP-1 RA in T2D treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- South Piedmont AHEC, Charlotte, North Carolina, USA.
- Abbott, Sylmar, California, USA.
- Abbott, Santa Clara, California, USA.
- Abbott Diabetes Care, Alameda, California, USA.
- Diabetes and Obesity Care LLC, Bend, Oregon, USA.
Zitieren
APA
Wright, E. E., Roberts, G. J., Chuang, J. S., Nabutovsky, Y., Virdi, N., & Miller, E. (2024). Initiating GLP-1 Therapy in Combination with FreeStyle Libre Provides Greater Benefit Compared with GLP-1 Therapy Alone. Diabetes Technology & Therapeutics, 26(10), 754-762. https://doi.org/10.1089/dia.2024.0015
Vancouver
Wright EE, Roberts GJ, Chuang JS, Nabutovsky Y, Virdi N, Miller E. Initiating GLP-1 Therapy in Combination with FreeStyle Libre Provides Greater Benefit Compared with GLP-1 Therapy Alone. Diabetes Technology & Therapeutics. 2024;26(10):754-762. doi:10.1089/dia.2024.0015
BibTeX
@article{Wright2024,
author = {Wright, Eugene E and Roberts, Gregory J and Chuang, Joyce S and Nabutovsky, Yelena and Virdi, Naunihal and Miller, Eden},
title = {Initiating GLP-1 Therapy in Combination with FreeStyle Libre Provides Greater Benefit Compared with GLP-1 Therapy Alone},
journal = {Diabetes Technology & Therapeutics},
year = {2024},
volume = {26},
number = {10},
pages = {754--762},
doi = {10.1089/dia.2024.0015}
}
EUVIMED